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Some concerns have been raised regarding the risk of late and very late stent thrombosis (ST) following drug-eluting stent
implantation. Despite remaining an uncommon complication of percutaneous coronary intervention, when ST occurs, it can
be catastrophic to the individual, commonly presenting as acute ST elevation myocardial infarction or sudden cardiac death. The
incidence and predictors of ST have been reported in the literature and the role of dual antiplatelet therapies in the avoidance
of such a complication remains vital. Ongoing studies are assessing the role of these therapies including platelet reactivity testing,
genetictestingandoptimumdurationoftherapy.Inaddition,newerpolymer-freeandbioabsorbablestentsareunderinvestigation
in the quest to potentially minimise the risk of ST.
1.Introduction
Drug-eluting stents (DES) were introduced into clinical
practice in order to reduce the rates of restenosis observed
with bare metal stents (BMS) for the treatment of coronary
artery disease [1–6]. However, despite the promising results,
some concerns have been raised regarding the potential in-
creased risk of late and very late stent thrombosis (ST)
following DES implantation. This is felt to be a consequence
of delayed endothelialization [7, 8]. The problem was ﬁrst
highlighted during the 2006 European Society of Cardiology
and World Congress of Cardiology Meeting in Barcelona,
Spain, when the results of two independent meta-analyses
were presented demonstrating a higher mortality with DES
[9]. This rapidly became known as the “ESC Firestorm,” and,
following this, an abundance of data from both randomized
clinical trials and multicenter registries have suggested an
increased risk of late and very late ST with the use of DES.
ST is a rare but usually catastrophic event, leading to
acute vessel closure, frequently associated with ST elevation
myocardial infarction (STEMI) or sudden cardiac death.
This paper aims to review the current data regarding ST,
the underlying causes and methods to reduce the risk. In
addition, there is an emphasis on the importance of dual
antiplatelet therapy (DAPT) and newer technologies under
development, which may in time lead to a vast reduction in
the incidence of ST.
2. Deﬁnition of Stent Thrombosis according
to the Academic Research Consortium
In an attempt to standardize the deﬁnition of ST, the
Academic Research Consortium (ARC) was formed in 2007,
proposing the criteria illustrated in Table 1 [10]. Addition-
ally, the timing of ST can be classiﬁed as acute (<24 hours
post procedure), early (24 hours to 30 days post procedure),
late (31 days to one year post procedure) and very late (>one
year post procedure).
3. Incidence of StentThrombosis
The actual incidence of ST reported in the literature depends
on the duration of follow-up utilized. During the early BMS
era, ST was demonstrated to be as high as 20.0% [11].
Followingthis,advancesintheﬁeldofinterventionalcardiol-
ogy, including high pressure post dilatation and importantly,
the addition of ticlopidine to aspirin, led to a signiﬁcant
decrease in the occurrence of ST [12, 13]. It was observed
that ST in BMS was uncommon after 30 days, due to com-
plete endothelialization within this time [14], which was2 Thrombosis
Table 1: ARC criteria for the diagnosis of stent thrombosis.
Deﬁnite Angiographic or pathologic evidence of ST
Probable Unexplained death within 30 days of the procedure or
MI at any time in the territory of previous PCI
Possible Unexplained death occurring 30 days post procedure
ST: stent thrombosis; MI: myocardial infarction; PCI: percutaneous coro-
nary intervention.
supported by a pooled analysis of a multicenter trial, when
over 80.0% of angiographically conﬁrmed ST occurred with-
in the ﬁrst 2 days of the procedure [15].
Similarly, most cases of ST occurring with DES occur
within 30 days of the procedure. In the Dutch ST registry
of over 21,000 patients who were treated with BMS and DES,
the majority of ST cases (>70.0%) were seen within the ﬁrst
month, with a cumulative incidence of deﬁnite ST of 2.1%
over 3 years [16]. There were no diﬀerences demonstrated in
the incidence of ST between BMS and DES. A further study
by the Bern-Rotterdam group, which assessed 8,146 patients
treated with DES (paclitaxel-eluting stents (PES) and sirol-
imus-eluting stents (SES)), reported a cumulative incidence
ofSTof3.3%at3years.Moreover,theannualincidenceofST
in this study was0.5% [17]. Conversely, a study by a Japanese
group (the J-Cypher registry) reported a lower incidence
following SES implantation of deﬁnite ST at 0.8% over 2
years follow-up [18]. Furthermore, a comprehensive meta-
analysis including 9,471 patients from 22 randomized trials,
demonstrated no diﬀerences in overall mortality (Hazard
Ratio (HR) 0.97; 95% Conﬁdence Interval (CI) 0.81–1.15;
P = 0.72) or myocardial infarction (MI) (HR 0.95; 95%
CI 0.79–1.13; P = 0.54) with DES compared with BMS. In
the observational studies arm of this paper, amongst 182,901
patients in 34 studies, there were signiﬁcant reductions in
mortality (HR 0.78; 95% CI 0.71–0.86) and MI (HR 0.87;
95% CI 0.78–0.97) with DES [19]. A further meta-analysis
of 13 randomized trials (7,352 patients) demonstrated that
therewasnoincreaseinSTwithDES(RR0.97;95%CI0.73–
1.28) over 2 years [20].
Most of the earlier data in DES is obtained from the ﬁrst
generation DES, with the newer second generation DES
thought to pose less risk. Studies evaluating their eﬀective-
ness over ﬁrst generation DES have reported few cases of
ST. Table 2 illustrates the incidence of ST in clinical trials
of second generation DES. The trial “Clinical Evaluation of
the Xience V Everolimus Eluting Coronary Stent System in
t h eT r e a t m e n to fS u b j e c t sw i t hd eN o v oC o r o n a r yA r t e r y
Lesions” (SPIRIT IV), which evaluated the results of ever-
olimus-eluting stents (EES) versus PES, reported ST in only
0.3% of EES patients in the ﬁrst year compared with 0.8%
of PES patients [21] .I nt h et r i a l“ At r i a lo fE v e r o l i m u s -
Eluting Stents and Paclitaxel-Eluting Stents for Coronary
Revascularization in Daily Practice” (COMPARE) which
randomized 1,800 patients to EES or PES, the incidence of
ST at one year was 1.0% following EES as compared with
3.0% in the PES group [22]. In addition, longer-term
follow-up to 3 years showed no statistical diﬀerence in the
occurrenceofST(EES1.2%versusSES1.7%)[23].Similarly,
the ENDEAVOR trials which evaluated the Zotarolimus-
elutingstent(ZES)reportedasigniﬁcantlylowerincidenceof
ST compared to ﬁrst generation DES [24–28]. Furthermore,
the RESOLUTE all-comers trial showed the rate of ST was
lower with EES compared with ZES (0.3% versus 1.2%;
P = 0.01) [29]. Additionally, a multicenter registry of 4,768
patients has been reported, which speciﬁcally assessed ST of
second generation DES (EES and ZES). This demonstrated
a cumulative incidence of deﬁnite ST in 1.0% of patients at
2 years follow-up. The incremental rate of ST from the ﬁrst
year to the second year was 0.25% [30]. Recently, data has
shownnooccurrenceofverylateSTat3yearsin102patients
undergoing primary angioplasty for STEMI [31].
4. ClassEffect
Fromtheavailabledata,itmaybeinferredthatthereisaclass
eﬀect between the diﬀerent drugs eluted from the permanent
polymer stents. In a meta-analysis of 18,023 patients from
randomized trials, there was an increased risk of deﬁnite late
ST with PES versus SES (HR 1.85; 95% CI 1.02–3.85; P =
0.041) [7], which was also shown in other registry studies
[34, 35]. Conversely, the “Sirolimus Eluting Stent compared
withPaclitaxelElutingStentforCoronaryRevascularization”
(SIRTAX) trial showed no diﬀerence between SES and PES
(resp., 4.6% versus 4.1%; P = 0.74) at 5 years follow-up [36].
Again, although ST is thought to be lower with the second
generation “limus” family of drugs than PES [21, 22], no
randomized studies have been adequately powered to assess
ST; therefore, further data in this ﬁeld is awaited.
5. PrognosisFollowing Stent Thrombosis
ManypatientswithSTpresenteitherassuddencardiacdeath
or as an acute STEMI. Those individuals who survive the
initial event are known to have a poor prognosis [37]. It is
important to emphasize that the case fatality rate in those
individuals suﬀering a ST has been demonstrated to be as
high as 45.0% in some series [8, 15, 16, 38–40]. A study
of 431 patients with angiographically conﬁrmed deﬁnite ST
demonstrated almost one in 5 patients with one deﬁnite ST
experienced another ST at follow-up, showing the high-risk
nature following the initial event [16].
Furthermore, a study of 985 patients who underwent
primary angioplasty for STEMI, which included 102 patients
with deﬁnite ST, demonstrated a higher occurrence of in-
hospital death or recurrent MI in those presenting with ST
rather than STEMI secondary to a de novo lesion (12.7%
versus 7.4%; P = 0.05) [41]. However, of note, these pa-
tients had a higher proportion of comorbidities, including
diabetes mellitus, chronic kidney disease and lower left
ventricular ejection fraction which may have contributed
to the diﬀerence in outcomes. Additionally, in those with
STEMI secondary to ST, there was a larger thrombus burden,
more frequent distal embolization and less successful results
from PCI [16, 42].Thrombosis 3
Table 2: Studies of second generation drug-eluting stents and the incidence of stent thrombosis.
Study Stent types Followup (months) Incidence of ST (%)
SORT OUT III [32] ZES versus SES 18 0.5 versus 1.0
Resolute all-comers [29] ZES versus EES 12 1.2 versus 0.3
ZEST [33] ZES versus SES versus PES 12 0.7 versus 0 versus 0.8
ENDEAVOR IV [24] ZES versus PES 12 0.7 versus 0.1
SPIRIT IV [21] EES versus PES 12 0.3 versus 0.8
COMPARE [22] EES versus PES 12 1.0 versus 3.0
SORT OUT III: Randomized Comparison of the Endeavor and the Cypher Coronary Stents in Non-Selected Angina Pectoris Patients; ZEST: Comparison of
the Eﬃcacy and the Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions; SPIRIT IV: Clinical
Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Subjects with de Novo Coronary Artery Lesions; COMPARE: A
Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary revascularization in Daily Practice; SES: Sirolimus-Eluting stent; PES: Paclitaxel-
eluting stent; ZES: Zotarolimus-eluting stent; EES: Everolimus-eluting stent.
6. Predictors of Stent Thrombosis
In general, ST occurs more frequently in complex patients
with complex lesions, for example, acute coronary syn-
dromes, diabetes mellitus, chronic kidney disease, small ves-
sels and multiple stents, including bifurcation lesions and
chronic total occlusion [8, 43, 44]. A summary of the un-
derlying patient, lesion and procedural characteristics which
are predictors of ST are illustrated in Table 3.
When a ST develops acutely, it is generally due to pro-
cedural-related factors, such as incomplete stent expansion,
residual edge dissection, the presence of thrombus and re-
duced TIMI (Thrombolysis In Myocardial Infarction) ﬂow
grade [8, 16, 17, 45]. Figure 1 demonstrates a case of acute
ST which occurred in a patient following EES for a chronic
total occlusion. The commonest reason for subacute and late
ST is the discontinuation of DAPT, which will be discussed
in more detail in a later section. Notably, risk factors for the
development of very late ST are not so well deﬁned. One
possible explanation for such late occurrence is incomplete
neointimal coverage as a result of delayed arterial healing,
ongoing vessel wall inﬂammation and late acquired stent
malapposition [46–50]. These phenomena have been ob-
servedinpatientswithDESbyreal-timeimagingstudies(an-
gioscopyandopticalcoherencetomography(OCT))[47,49–
51] and also in some autopsy studies of stented segments in
patients with very late ST [46]. Figure 2 demonstrates a def-
inite ST in a patient 18 months following SES implantation
and evidence of thrombus on malapposed struts.
7.ProceduralOptimization
InviewoftheclinicalcourseassociatedwithaST,meticulous
attention must be made to reduce the risk from the outset.
Risk factors pertaining to the patients’ history and lesion
characteristics are non-modiﬁable; however, the procedure
can be performed optimally to reduce the incidence of ST.
Firstly, it is important to adequately screen the patient, to
assess likely adherence to the necessary DAPT regimen, the
bleeding risk and the need for any planned surgical proce-
dures in the following 12 months.
The decision then needs to be made regarding the anti-
coagulation of choice during the procedure. However, this
also carries risk, as bleeding complications may not be
insignificant. Conventionally, unfractionated heparin has
been the anticoagulant of choice in those undergoing PCI,
often in combination with a glycoprotein IIb/IIIa inhibitor.
In the “Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications” (CADILLAC) trial
[52], abciximab use was an independent predictor of no ST
(HR 0.27; 95% CI 0.09–0.86; P = 0.026). However, recently
bivalirudin, a direct thrombin inhibitor, has become more
widespread in use. In the “Harmonizing Outcomes with
RevascularizationandStentsinAcuteMyocardialInfarction”
(HORIZONS-AMI) trial which randomised 3,602 patients
withSTEMIundergoingprimaryangioplastytoheparinplus
glycoprotein IIb/IIIa inhibitor versus bivalirudin monother-
apy, acute ST occurred in patients assigned to bivalirudin
more frequently (1.4% versus 0.3%; P<0.001) with con-
versely ST after 24 hours occurring less frequently (2.8%
versus 4.4%, P = 0.02). Notably, there was no diﬀerence in
the cumulative rates of ST at 2 years between the 2 groups
(4.3% versus 4.6%; P = 0.73) [53].
Furthermore, good lesion preparation (considering the
use of rotational atherectomy in the presence of severely
calciﬁed lesions), use of properly sized stents and postdi-
latation with non compliant balloons, according to intravas-
cular ultrasound (IVUS) guidance, may help adequate stent
expansionandapposition.Thespacebetweenthestentstruts
and vessel wall which is present when there is malapposition
leads to an area of sluggish ﬂow, which can allow thrombus
formation. It is therefore essential to choose the correct stent
size and perform eﬀective high pressure postdilatation to
reduce this risk. Adequate stent expansion on IVUS has been
linked to lower ST at both 30 days and 12 months [54].
This can also ensure there are no remaining edge dissections
which may be a nidus for ST.
Newer imaging modalities, such as OCT, may become
a useful tool to help assessment of the substrates for ST
development, thereby allowing optimization of the initial
procedure. As discussed earlier, incomplete stent apposition
may be associated with the formation of thrombus; on OCT,
thrombus was seen signiﬁcantly more frequently in struts
that were not fully apposed compared to those with good
apposition (20.6% versus 2.0%; P<0.001) [55]. Additional-
ly,ithasbeenshownthatDEShaveahigherrateofuncovered
and malapposed struts than BMS with OCT imaging [56].4 Thrombosis
Table 3: Predictors of stent thrombosis.
Patient characteristics Lesion characteristics Procedural characteristics
Diabetes mellitus Long segment of disease Stent underexpansion
Chronic kidney disease Small diameter vessel Stent malapposition
Acute presentation Saphenous venous graft Edge dissection
Current smoker Chronic total occlusion Strut fracture
Reduced left ventricular function Bifurcation lesion Multiple stent implantation and stent overlap
Cancer Geographic miss and residual stenosis
DAPT non-responsiveness Reduced TIMI ﬂow alter procedure
Premature cessation of DAPT
Advanced age
Thrombocythemia
H y p e r s e n s i t i v i t yt op o l y m e ro rd r u g
DAPT: dual antiplatelet therapy; TIMI: thrombolysis in myocardial infarction.
(a) (b)
(c) (d)
Figure 1: An illustration of how catastrophic stent thrombosis can be when it occurs. Panel (a) shows a chronic total occlusion of the left
anterior descending coronary artery which was successfully opened (Panel (b)) with the implantation of everolimus-eluting stents (resp.,
3.5 × 33mm and 2.75 × 33mm). Twenty-four hours following the procedure, the patient became markedly hypotensive and symptomatic
forangina,withEKGshowingSTelevationintheanteriorleads.Panel(c)demonstratesanacutestentthrombosisattheostiumofthevessel.
Finally, Panel (d) shows the results following thrombus aspiration and plain optimal balloon angioplasty.Thrombosis 5
(a) (b) (c)
Figure 2: An illustration of a very late stent thrombosis 18 months following Sirolimus-eluting stent implantation in the circumﬂex
artery. Panel (a) demonstrates the angiographic image. Panel (b) shows evidence of thrombus removed with a thrombus extraction system,
and, ﬁnally Panel (c) illustrates malapposed struts and adherent thrombus following predilatation and assessment with optical coherence
tomography.
8. CorrelationbetweenDualAntiplatelet
Therapy and Stent Thrombosis
The current recommendations from the American College
of Cardiology/American Heart Association/Society for Car-
diovascular Angiographic Intervention are that, following
DES implantation, patients should receive clopidogrel (or
an alternative thienopyridine) in addition to aspirin for a
minimum of 12 months, unless there is a high bleeding risk
or urgent circumstances arise [57]. The Task Force on my-
ocardial revascularization of the European Society of Car-
diology and the European Association for Cardiothoracic
Surgery is less speciﬁc and state that convincing data exists
only for continuation of DAPT up to 6 months [58].
However, the optimal duration after DES implantation
remains unknown. The discontinuation of DAPT was the
most powerful predictor of ST during the ﬁrst 6 months fol-
lowing stent implantation in a cohort of over 3,000 patients
(HR 13.74; 95% CI 4.04–46.68; P<0.001) [59]. This was
conﬁrmed by a study by Schulz et al. in over 6,000 pa-
tients with 4-years follow up [60]. Furthermore, it has been
demonstrated that ST occurred in 29.0% of patients who
prematurely discontinued DAPT [8]. Conversely, the Bern/
Rotterdam registry of over 8,000 patients demonstrated no
diﬀerences in those treated with clopidogrel for 12 months
following DES implantation compared with those treated for
only 3–6 months.
Alternatively, it has been suggested that patients treated
with clopidogrel for 24 months had improved cumulative
survival compared to those treated for 12 months [61].
However, it has been shown in a randomized trial of 2,701
patients who were free of major adverse cardiovascular and
cerebrovascular events (MACCE) and major bleeding events
for 12 months alter PCI receiving 12 versus 24 months of
clopidogrel that the cumulative occurrence of deﬁnite ST at
24 months afterDES wasidentical in patients whocontinued
clopidogrel until 24 months (0.4% versus 0.4%; P = 0.76)
[62]. The “PROlonging Dual-antiplatelet treatment after
Grading stent-Induced hyperplasia” [63] (PRODIGY) study
was presented at the European Society of Cardiology Scien-
tiﬁc Congress, Paris, 2011 which randomized 2,013 patients
on an intention-to-stent basis to EES (n = 501), PES (n =
505), ZES (n = 502), or BMS (n = 505). After 30 days, 1,970
were eligible for randomization to either 6 months DAPT
(n = 983) or 24 months DAPT (n = 987) and followed up
for2years.ThisshowednobeneﬁtofprolongedDAPTinthe
incidenceofischemiceventsatthecostofanincreasedriskof
major bleeding (HR 2.17; 95% CI 1.44–3.22; P = 0.00018).
Theoptimaldurationiscurrentlybeingassessedinanumber
of randomized trials illustrated in Table 4.
A number of factors have been thought to be implicated
in the development of ST including clopidogrel resistance,
hypersensitivity to the stent polymer, drug interactions and
the discontinuation of clopidogrel within the ﬁrst 6 months
[59]. The measurement of platelet function on DAPT can
enable those patients at highest risk to be identiﬁed [66–
68], as it is known individual responses to clopidogrel vary
signiﬁcantly[69].Onequarterofindividualsmayberesistant
to the platelet-inhibiting eﬀects of clopidogrel [70, 71]. A
recent meta-analysis of over 3,000 patients demonstrated
that high on treatment platelet reactivity tested by the
VerifyNow assay (Accumetrics, San Diego, California, USA),
deﬁned as a P2YC12 Reaction Unit (PRU) of greater than or
equal to 230, was associated with ST (HR 3.11; 95% CI 1.50–
6.46; P = 0.002) [72]. Moreover, Parodi et al. demonstrated
in 1,789 patients undergoing PCI who had platelet reactivity
prospectively assessed using light transmittance aggregom-
etry that a high residual platelet reactivity (≥70% platelet
aggregation) led to a higher incidence of ST (6.1% versus
2.9%; P = 0.01) [73]. However, even if we are aware of
this, no beneﬁt was shown in the “Gauging Responsiveness
With a VerifyNow Assay: Impact on Thrombosis and Safety”
(GRAVITAS) trial following double dose clopidogrel if there
was high on treatment platelet reactivity [74]. In this study,
the composite rate of cardiovascular death, MI, or ST was
low in both groups (2.3%) at 6 months. However, it is
important to note that less than half of patients randomized
to clopidogrel 150mg achieved appropriate variability in6 Thrombosis
Table 4: Studies of ongoing randomized trials to assess optimal clopidogrel duration.
Study Patient population Clopidogrel duration (months) Primary endpoint
ISAR-SAFE
[64]
Patients on clopidogrel 6
months alter DES 6v e r s u s1 2 Composite of death, MI, ST, stroke and major bleeding
DAPT [65] All-comers 12 versus 30 Composite of death, MI, SI, stroke and major bleeding
DAPT-STEMI All STEMI patients 6 versus 12 MACCE
SECURITY Second-generation DES 6 versus 12 Deﬁnite/probable ST
RESET All-comers 3 Composite of cardiovascular death, MI, ST and major bleeding
OPTIMIZE Stable CAD and
NSTEMI 3v e r s u s1 2 Composite of death, MI, stroke and major bleeding
ISAR-SAFE: Intracoronary Stenting and Antithrombotic Regimen: Safety and Eﬃcacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting;
DAPT: Dual Antiplatelet Therapy Study; STEMI: ST Elevation Myocardial Infarction; SECURITY: SECond generation drUg-eluting stents implantation
followed by six-versus twelve-month dual antIplatElet therapy; RESET: A New Strategy Regarding Discontinuation of Dual Antiplatelets; OPTIMIZE:
Optimized Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus Eluting Stent in the Real World Clinical Practice; DES:
drug-elutingstent;CAD:coronaryarterydisease;NSTEMI:non-STelevationmyocardialinfarction;MI:myocardialinfarction;ST:stentthrombosis;MACCE:
major adverse cardiovascular and cerebrovascular events.
antiplatelet response, which may have contributed to the
lack of observed clinical eﬀect. In addition, due to the lower
than expected event rates, the study was underpowered to
detect the clinical eﬃcacy of high-dose clopidogrel. Another
randomized study, “Testing Platelet Reactivity in Patients
Undergoing Elective Stent Placement on Clopidogrel to
Guide Alternative Therapy With Prasugrel” (TRIGGER-
PCI), comparing prasugrel to clopidogrel for those with high
platelet reactivity was terminated early due to futility as high
on clopidogrel platelet reactivity (>208PRU by VerifyNow)
was observed less frequently than expected and there was
a low occurrence of the primary endpoint of cardiac death
or MI. There are a number of ongoing studies which aim
to assess the utilization of platelet reactivity testing and
optimization of DAPT following PCI, which are illustrated
in Table 5.
Clopidogrel is a prodrug which requires conversion to an
active metabolite to provide its eﬀects and resistance can be
due to a genetic variation in one of the cytochrome P450 he-
patic enzymes necessary for this, particularly the CYP2C19
allele [75]. Patients with polymorphisms in this gene, which
accounts for only 5–12% of clopidogrel response variability
[76, 77], have more adverse clinical events following PCI.
[78, 79]. Indeed, this gene has been independently shown
to be associated with early ST [80]. Despite this, currently
genetic testing is not widely utilized in patients requiring
stent implantation; however, the “Escalating Clopidogrel by
Involving a Genetic Strategy—Thrombolysis In Myocardial
Infarction 56” (ELEVATE-TIMI) study was recently reported
[81]. The aim of this study was to assess whether higher
doses of clopidogrel (up to 300mg) improved responses
in the setting of loss of function CYP2C19 genotypes. The
genotypes of 333 patients with stable coronary artery disease
were established, and it was shown that a dose of 225mg
clopidogrel daily in CYP2C19 heterozygotes achieved levels
of platelet reactivity similar to that seen with the standard
75mg dose in non-carriers. However, in homozygotes, doses
of even 300mg did not result in comparable degrees of
platelet inhibition. A number of studies are currently ongo-
ingtofurtherassesstheroleofCYP2C19pharmacogenomics
(Table 6). Notably, the US Food and Drug Administration
has added a box warning to clopidogrel about the reduced
eﬀectiveness in those patients who are poor metabolizers of
the drug.
IfapatientdevelopsSTwhilefullycompliantwithDAPT,
thenconsiderationshouldbegiventothemodiﬁcationofthe
drug regimen. Newer antiplatelet agents, including prasugrel
[82]a n dt i c a g r e l o r[ 83], are now available which have been
shown to be more potent, with a consequent reduction in ST
[84, 85]. Non responders to clopidogrel also respond well to
these newer agents [86, 87]. In patients with acute coronary
syndromes, the rates of ST have been reduced by substituting
clopidogrel with these drugs, at the risk of increased bleeding
[88, 89]. There is also the option of adding in therapy such as
cilostazol, a phosphodiesterase inhibitor [90]. This has been
shown in a registry study of 3,099 patients to reduce the risk
of ST at 12 months as compared to DAPT only (HR 0.136;
95% CI 0.035–0.521; P = 0.0036) [91], with no increase in
bleeding complications. However, most studies of cilostazol
have been performed in Asians and have not been validated
in the Western population.
Finally, drug interactions from other hepatic enzyme in-
hibitors can result in reduced eﬀectiveness of clopidogrel.
Importantly, in recent years, there has been concern regard-
ing the use of concomitant proton pump inhibitors (PPIs)
with clopidogrel [92]. However, the “Clopidogrel with or
without omeprazole in coronary artery disease” (COGENT)
trial which randomly assigned 3,873 patients on DAPT to
omeprazoleorplacebodemonstratednoapparentcardiovas-
cularinteractionbetweenthedrugs[93].However,thisstudy
wasterminatedearlyandthereforewasunderpoweredforthe
endpoint.TheAmericanHeartAssociationguidelinesdonot
prohibit the use of PPIs, yet highlight the potential risks and
beneﬁts of coadministering with clopidogrel [94]. Ongoing
studies are assessing the role of CYP2C19 in the drug
interaction between clopidogrel and PPIs: the “Evaluation
of the Inﬂuence of Statins and Proton Pump Inhibitors on
Clopidogrel Antiplatelet Eﬀects” (SPICE) trial and the Inﬂu-
enceofCYP2C19GeneticVariantsonClopidogrelinHealthy
Subjects Study.Thrombosis 7
Table 5: A table to illustrate ongoing studies utilizing the results of platelet reactivity testing to assess outcomes following PCI.
Study Number of
patients
Patient
population
Platelet reactivity
value Antiplatelet therapy Primary endpoint
ARCTIC 2,500 Elective PCI <15% GPIIb/IIIa inhibitors Death, MI, Stroke, TVR, ST
DANTE 442 NSTEMI PRU > 240 Clopidogrel 75mg versus
Clopidogrel 150mg Cardiovasculardeath,MIandTVR
ARCTIC: Monitored Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation and Interruption Versus Continuation
of Double Antiplatelet Therapy; DANTE: Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition; PCI: percutaneous coronary intervention;
NSTEMI:Non-STelevationmyocardialinfarction;GPIIb/IIIa:GlycoproteinIIb/IIIainhibitor;MI:myocardialinfarction;TVR:targetvesselrevascularization;
ST: stent thrombosis; PRU: P2YC12 reaction unit.
Table 6: Ongoing studies assessing pharmacogenomics and antiplatelet therapy.
Study Number of
patients Patient population Therapy Primary endpoint
GIFT NA All-comers
undergoing PCI
Tailored clopidogrel versus standard clopidogrel
according to platelet reactivity and genetic type
Residual platelet ac-
tivity
TARGET-PCI 1,500 Nonemergent PCI Tailored with clopidogrel and prasugrel to results
of platelet reactivity and genetic type MACE
CLOVIS-2 120 Post-MI Clopidogrel 300mg versus Clopidogrel 600mg in
2 genetic CYP2C19 types
Inhibition of resid-
ual platelet activity
6 hours following
clopidogrel
PREDICT 42 Stable CAD
Those with high residual platelet activity on
clopidogrel and genotyped for CYP2C19 treated
with double dose clopidogrel
Change in residual
platelet activity
GeCCO 14,600 Recent ACS Genotype-guided comparison of clopidogrel in
extensive metabolizers and prasugrel
Cardiovascular
death, nonfatal MI,
or nonfatal stroke
GIFT: Genotype Information and Functional Testing; TARGET-PCI: Thrombocyte Activity Reassessment and Genotyping for PCI; CLOVIS-2: Clopidogrel
and response Variability Investigation Study 2; PREDICT: Pilot Study on the Eﬀect of High Clopidogrel Maintenance Dosing; GeCCO: Genotype Guided
Comparison of Clopidogrel and Prasugrel Outcomes Study; PCI: percutaneous coronary intervention; MI: myocardial infarction; CAD: coronary artery
disease; ACS: acute coronary syndrome; MACE: major adverse cardiovascular event.
9.Impact ofNew Technologies
Currently, there is much interest in the development of new
technologies to improve safety outcomes, including a reduc-
tion in ST. It has been known for a number of years that
durable polymers can cause local arterial injury [95]. Non
erodible polymers provoke chronic eosinophilic inﬁltration
within the arterial wall, suggestive of hypersensitivity reac-
tions [96, 97]. Concerns regarding the eﬀects of these poly-
mershadledtothedesignofstentswitheitherbiodegradable
polymers or indeed no polymers, which are illustrated in
Table 7.
T h e“ L i m u sE l u t e df r o mAD u r a b l ev e r s u sE R o d a b l e
Stent coating” (LEADERS) trial randomized 1,707 patients
to either SES or biolimus A9-eluting stents (BES). The
latter stent elutes biolimus from a polylactide biodegradable
polymer applied to the abluminal surface of the stent which
is fully metabolized within 6–9 months. At 3 years follow up,
the rate of deﬁnite ST was 2.2% for the BES and 2.9% for the
SES (HR 0.78; 95% CI 0.43–1.43; P = 0.43). However, inter-
estingly, ST increased at a lower rate of 0.2% from one to 3
years for the BES compared with 0.9% for the SES. In addi-
tion, patients who had stopped DAPT did not appear to have
any additional events at 3 years, with conversely in the SES
group, there were development of events [98]. Furthermore,
this may be explained by an OCT substudy of the LEADERS
trial which demonstrated that BES had better strut coverage
at 9 months than SES [99].
Further stents with biodegradable polymers are being
developed and are showing promising results in early trials.
The Biofreedom stent (Biosensors, Morges, Switzerland),
which again is a BES, has demonstrated minimal delayed ar-
terial healing [100]. Additionally, the Synergy stent (Boston
Scientiﬁc, Natick, MA, USA) which has a bioabsorbable pol-
ymer and everolimus drug combination has recruited pa-
tients to the EVOLVE study (non-inferiority trial to assess
the safety and performance of the evolution coronary stent),
and the results are awaited. Finally, the CRE8 (CID, Saluggia,
Italy) stent has recently gained CE mark. This is a unique
polymer free abluminal reservoir technology together with
a new amphilimus formulation which allows controlled and
targeted drug elution to the artery. The results of the “Inter-
national Randomized Comparison between DES Limus
Carbostent and Taxus Drug Eluting Stents in the Treatment
of De Novo Coronary Lesions” (NEXT) trial were presented
at EuroPCR, Paris, France, in 2011 which demonstrated no
ST at 180 days.
Morerecently,completelybioabsorbablestentshavebeen
developedtoallowcompletestentresorption,arterialhealing8 Thrombosis
Table 7: Newer stents.
Stent Stent Platform Polymer Drug Company
Biomatrix Stainless steel PLA Biolimus-A9 Biosensors Inc., Newport Beach, CA, USA
JACTAX Stainless steel PLA Paclitaxel Boston Scientiﬁc, Natick, MA, USA
Nobori Stainless steel PLA Biolimus-A9 Termumo Medical Corp., Tokyo, Japan
Synergy Platinum chromium PLA Everolimus Boston Scientiﬁc, Natick, MA, USA
Janus Flex Stainless steel Carboﬁlm Tacrolimus Sorin, Italy
Biofreedom Stainless steel None Biolimus-A9 Biosensors Inc., Newport Beach, CA, USA
Cre8 Cobalt chromium None Amphilimus CID, Saluggia, Italy
Amazonia Pax Cobalt chromium None Paclitaxel Minvasys, Paris, France
VESTAsync Stainless steel None Sirolimus MIV Therapeutics, Atlanta, GA, USA
Yukon Choice Stainless steel None Sirolimus Translumina, Hechingen, Germany
PLA: polylactic acid.
and restoration of normal vascular function. As stent struts
theoretically disappear, issues related to late persistent strut
malapposition and chronically uncovered struts, including
ST, become irrelevant. Additionally, there is elimination of
chronic sources of vessel irritation and inﬂammation which
could potentially reduce the need for prolonged DAPT. The
“Clinical Evaluation of the Bioabsorbable Vascular Solutions
Everolimus Eluting Coronary Stent System in the Treatment
of Patients with Single De Novo Coronary Artery Lesions”
(ABSORB) trial was a prospective multicenter, open-label,
ﬁrst-in-man study that assessed the bioabsorbable polymer
stent in 30 patients. This has shown no cases of ST at 4 years
follow up [101]. The results of the second cohort of the
ABSORB trial with the second generation bioabsorbable
stent have demonstrated no cardiovascular death at 12
months follow-up [102]. Currently, patients are being
recruited for ABSORB Extend which aims to recruit 1,000
patients and follow up for the occurrence of ST. There are
several bioabsorbable stents in development and in clinical
trials. The REVA stent (REVA medical Inc., San Diego, CA,
USA) coated with paclitaxel and the Bioabsorbable Thera-
peutics stent (Bioabsorbable Therapeutics Inc., Menlo Park,
CA, USA) coated with sirolimus are currently being tested.
10. Conclusions
The occurrence of a ST is rare, however, remains one of
the most feared complications following PCI, due to the
potential catastrophic consequences. There are a number of
factors that may lead to the development of a ST and it is
essential that we optimize PCI technique and importantly
DAPT regimens in all patients undergoing PCI. Newer stents
are being developed at rapid rates, and future large-scale
randomized trials may help in the decision making regarding
these issues in an aim to reduce this dramatic event.
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